Remoxiprida [Inn-Spanish]
Brand names,
Remoxiprida [Inn-Spanish]
Analogs
Remoxiprida [Inn-Spanish]
Brand Names Mixture
Remoxiprida [Inn-Spanish]
Chemical_Formula
C16H23BrN2O3
Remoxiprida [Inn-Spanish]
RX_link
No information avaliable
Remoxiprida [Inn-Spanish]
fda sheet
Remoxiprida [Inn-Spanish]
msds (material safety sheet)
Remoxiprida [Inn-Spanish]
Synthesis Reference
No information avaliable
Remoxiprida [Inn-Spanish]
Molecular Weight
371.269 g/mol
Remoxiprida [Inn-Spanish]
Melting Point
No information avaliable
Remoxiprida [Inn-Spanish]
H2O Solubility
74 mg/L
Remoxiprida [Inn-Spanish]
State
Solid
Remoxiprida [Inn-Spanish]
LogP
3.511
Remoxiprida [Inn-Spanish]
Dosage Forms
Tablet
Remoxiprida [Inn-Spanish]
Indication
For the treatment of schizophrenia.
Remoxiprida [Inn-Spanish]
Pharmacology
Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.
Remoxiprida [Inn-Spanish]
Absorption
Rapidly absorbed. Absolute bioavailability is 90%.
Remoxiprida [Inn-Spanish]
side effects and Toxicity
No information avaliable
Remoxiprida [Inn-Spanish]
Patient Information
No information avaliable
Remoxiprida [Inn-Spanish]
Organisms Affected
Humans and other mammals